Researchers have investigated the use of HLA-matched or HLA-haploidentical allogeneic CD19-redirected CAR-Ts (M-CAR-Ts and H-CAR-Ts, respectively) for the treatment of R/R B-ALL patients to evaluate which one can result in better clinical outcomes (106). This evidence concerns the gene CD19 and acute lymphoblastic leukemia.